Acceleron Pharma
XLRN
XLRN was delisted on the 19th of November, 2021.
125 hedge funds and large institutions have $1.21B invested in Acceleron Pharma in 2015 Q4 according to their latest regulatory filings, with 26 funds opening new positions, 49 increasing their positions, 32 reducing their positions, and 10 closing their positions.
160% more first-time investments, than exits
New positions opened: 26 | Existing positions closed: 10
100% more capital invested
Capital invested by funds: $607M → $1.21B (+$606M)
53% more repeat investments, than reductions
Existing positions increased: 49 | Existing positions reduced: 32
13% more funds holding
Funds holding: 111 → 125 (+14)
25% less funds holding in top 10
Funds holding in top 10: 4 → 3 (-1)
49% less call options, than puts
Call options by funds: $9.66M | Put options by funds: $19.1M
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Millennium Management
New York
|
+$19.9M |
| 2 |
SAM
Sectoral Asset Management
Montreal,
Quebec, Canada
|
+$18.3M |
| 3 |
DM
Deerfield Management
New York
|
+$7.68M |
| 4 |
State Street
Boston,
Massachusetts
|
+$6.54M |
| 5 |
GIM
Granahan Investment Management
Waltham,
Massachusetts
|
+$5.97M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Adage Capital Partners
Boston,
Massachusetts
|
-$19.1M |
| 2 |
QF
QVT Financial
New York
|
-$7.97M |
| 3 |
T. Rowe Price Associates
Baltimore,
Maryland
|
-$7.04M |
| 4 |
Citadel Advisors
Miami,
Florida
|
-$3.3M |
| 5 |
NLVP
New Leaf Venture Partners
New York
|
-$2.85M |
XLRN Hedge Fund Activity: Q4 2015 in Review
125 of the 3,812 institutional investors tracked by Wall St. Rank reported a position in Acceleron Pharma (XLRN) for Q4 2015, worth a combined $1.21B — up 100% from $607M a quarter earlier.
Buyers outnumbered sellers: 26 funds opened new XLRN positions and 10 closed out — a net gain of 16 holders — while 49 added to existing stakes and 32 trimmed.
The largest buyer was Millennium Management, adding an estimated $19.9M. The largest seller was Adage Capital Partners, cutting an estimated $19.1M.
- 125 institutional investors held Acceleron Pharma (XLRN) as of Q4 2015, up from 111 in Q3 2015.
- Funds reported $1.21B of Acceleron Pharma stock for Q4 2015, up 100% quarter-over-quarter.
- 26 funds opened new Acceleron Pharma positions in Q4 2015 and 10 closed out, a net change of +16 holders.
- The largest Acceleron Pharma buyer in Q4 2015 was Millennium Management, an estimated $19.9M added.
- The largest Acceleron Pharma seller in Q4 2015 was Adage Capital Partners, an estimated $19.1M sold.
Based on aggregated 13F filings for Q4 2015.